1. Current treatment of COVID-19 in renal patients: hope or hype?
- Author
-
Roberto P, Francesco L, Emanuela C, Giorgia G, Pasquale N, and Sara D
- Subjects
- Adenosine Monophosphate analogs & derivatives, Adenosine Monophosphate therapeutic use, Adrenal Cortex Hormones therapeutic use, Alanine analogs & derivatives, Alanine therapeutic use, Amides therapeutic use, Antibodies, Monoclonal therapeutic use, COVID-19, Cobicistat therapeutic use, Coronavirus Infections drug therapy, Darunavir therapeutic use, Drug Combinations, Humans, Kidney drug effects, Kidney injuries, Kidney physiopathology, Lopinavir therapeutic use, Pandemics, Pneumonia, Viral drug therapy, Pyrazines therapeutic use, Renal Insufficiency, Chronic complications, Renal Replacement Therapy methods, Ritonavir therapeutic use, Coronavirus Infections complications, Pneumonia, Viral complications, Renal Insufficiency, Chronic drug therapy
- Abstract
To date the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), known as COVID-19, is for clinicians the most difficult global therapeutic problem. In this landscape, the management of patients with chronic kidney disease, acute kidney injury or patients undergoing immunosuppressant therapies for kidney transplant or glomerular diseases, represent a clinical challenge for nephrologists, especially in patients with severe acute lung involvement. Therefore in this setting, due to the lack of anti-COVID treatment schedules, tailored management is mandatory to reduce the side effects, as consequence of impaired renal function and drugs interactions. We report the main treatment actually used against SARS-CoV-2, underlining its possible use in the nephropatic patients and the central role of nephrologists to improve the clinical outcome.
- Published
- 2020
- Full Text
- View/download PDF